CMS Restricts Coverage For Devices More Than Drugs, Study Finds
This article was originally published in The Gray Sheet
Executive Summary
Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.